Literature DB >> 3339332

Production of interferon alpha by dengue virus-infected human monocytes.

I Kurane1, F A Ennis.   

Abstract

Human monocytes appear to be very important in the pathogenesis of dengue infection. They are thought to be the most active sites of virus replication during dengue infection. We have analysed interferon (IFN) production by dengue virus from peripheral blood mononuclear cells (PBMC). IFN activity was first detected at 12 h after infection of monocytes and reached a maximum level by 48 h. Non-adherent PBMC depleted of monocytes did not produce detectable levels of IFN, and did not contain dengue antigen-positive cells after exposure to dengue virus. The IFN produced was characterized as IFN-alpha by neutralization tests using specific antisera to HuIFN-alpha, HuIFN-beta and HuIFN-gamma, and by radioimmunoassay. The culture fluids of dengue virus-infected monocytes, which contained IFN-alpha, were able to inhibit infection of human monocytes by dengue virus. These results suggest that IFN-alpha produced by dengue virus-infected monocytes may play an important role in controlling primary dengue virus infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3339332     DOI: 10.1099/0022-1317-69-2-445

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  26 in total

1.  Dengue virus infection of human skin fibroblasts in vitro production of IFN-beta, IL-6 and GM-CSF.

Authors:  I Kurane; J Janus; F A Ennis
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 2.  Dengue virus life cycle: viral and host factors modulating infectivity.

Authors:  Izabela A Rodenhuis-Zybert; Jan Wilschut; Jolanda M Smit
Journal:  Cell Mol Life Sci       Date:  2010-04-06       Impact factor: 9.261

3.  Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.

Authors:  M S Diamond; T G Roberts; D Edgil; B Lu; J Ernst; E Harris
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis.

Authors:  D H Libraty; S Pichyangkul; C Ajariyakhajorn; T P Endy; F A Ennis
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Retinoic acid inducible gene-I and melanoma differentiation-associated gene 5 are induced but not essential for dengue virus induced type I interferon response.

Authors:  Cheng-Feng Qin; Hui Zhao; Zhong-Yu Liu; Tao Jiang; Yong-Qiang Deng; Xu-Dong Yu; Man Yu; E-De Qin
Journal:  Mol Biol Rep       Date:  2010-11-27       Impact factor: 2.316

6.  Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide.

Authors:  Yun-Chi Chen; Sheng-Yuan Wang
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Cardif-mediated signaling controls the initial innate response to dengue virus in vivo.

Authors:  Stuart T Perry; Tyler R Prestwood; Steven M Lada; Chris A Benedict; Sujan Shresta
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

8.  Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells.

Authors:  U Kontny; I Kurane; F A Ennis
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

Review 9.  Micronutrients and dengue.

Authors:  Sundus Ahmed; Julia L Finkelstein; Anna M Stewart; John Kenneth; Mark E Polhemus; Timothy P Endy; Washington Cardenas; Saurabh Mehta
Journal:  Am J Trop Med Hyg       Date:  2014-09-08       Impact factor: 2.345

10.  Both viremia and cytokine levels associate with the lack of severe disease in secondary dengue 1 infection among adult Chinese patients.

Authors:  Yangbo Tang; Zhihua Kou; Fuchun Zhang; Xian Yao; Shengyong Liu; Jingming Ma; Yusen Zhou; Wei Zhao; Xiaoping Tang; Xia Jin
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.